Inhibitory G Protein Overexpression Provides Physiologically Relevant Heart Rate Control in Persistent Atrial Fibrillation
- 9 November 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (19) , 3115-3120
- https://doi.org/10.1161/01.cir.0000147185.31974.be
Abstract
Background— The need for new treatment strategies for cardiac arrhythmias has motivated our continuing development of gene therapeutic options. Previously, we reported a decreased heart rate in an acute model of atrial fibrillation after atrioventricular nodal gene transfer. Here, we expand those observations to persistent atrial fibrillation and severe heart failure. Methods and Results— After 3 weeks of atrial fibrillation, domestic swine received atrioventricular nodal gene transfer with adenoviruses encoding β-galactosidase (β-gal), wild-type Gα i2 (wtGi), or constitutively active mutant (cGi). Heart rates in awake, alert animals were not altered by β-gal or wtGi. cGi caused a sustained 15% to 25% decrease in heart rate. The wtGi effect became evident with sedation. A tachycardia-induced cardiomyopathy was present before gene transfer. In the β-gal group, cardiomyopathy worsened over time. In the wtGi group, the condition improved slightly, and in the cGi group, ejection fraction was near normal at the end of the study. TUNEL staining results corroborated this finding. Conclusions— cGi overexpression in the porcine atrioventricular node causes physiologically relevant heart rate control in persistent atrial fibrillation. These data advance the development of gene therapy as a potential treatment for common cardiac arrhythmias.Keywords
This publication has 19 references indexed in Scilit:
- Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failureCardiovascular Research, 2004
- A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial FibrillationNew England Journal of Medicine, 2002
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002
- Biological pacemaker created by gene transferNature, 2002
- Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energyJournal of the American College of Cardiology, 2000
- Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimensJournal of the American College of Cardiology, 1999
- Persistence in muscle of an adenoviral vector that lacks all viral genesProceedings of the National Academy of Sciences, 1997
- Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarctionThe Lancet, 1996
- Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.The Journal of cell biology, 1992
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991